奥希替尼用于罕见表皮生长因子受体（EGFR）突变：在马群中驱赶独角兽。 - Suppr

Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses.

作者信息

Dougherty Sean C, Gentzler Ryan D

机构信息

Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

出版信息

Transl Cancer Res. 2025 Feb 28;14(2):670-675. doi: 10.21037/tcr-24-1936. Epub 2025 Feb 26.

DOI:10.21037/tcr-24-1936

PMID:40104749

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912071/

Abstract

摘要

相似文献

Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses.

Transl Cancer Res. 2025 Feb 28;14(2):670-675. doi: 10.21037/tcr-24-1936. Epub 2025 Feb 26.

Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.

Curr Oncol. 2022 Jan 9;29(1):255-266. doi: 10.3390/curroncol29010024.

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8.

A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.

Ann Palliat Med. 2022 Mar;11(3):1121-1125. doi: 10.21037/apm-21-2653.

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.

Chin Med J (Engl). 2023 Nov 5;136(21):2551-2561. doi: 10.1097/CM9.0000000000002468.

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.

JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013.

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.

Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.

Comparation of EGFR-TKI (EGFR tyrosine kinase inhibitors) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis.

Medicine (Baltimore). 2023 Jul 28;102(30):e34483. doi: 10.1097/MD.0000000000034483.

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14.

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis.

Lung Cancer. 2025 Jun 19;205:108629. doi: 10.1016/j.lungcan.2025.108629.

本文引用的文献

Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.

Lung Cancer. 2024 Sep;195:107926. doi: 10.1016/j.lungcan.2024.107926. Epub 2024 Aug 10.

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.

JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013.

Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions.

N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.

Overall Survival with Osimertinib in Resected -Mutated NSCLC.

N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4.

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.

Oncologist. 2023 Jun 2;28(6):e397-e405. doi: 10.1093/oncolo/oyad111.

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).

J Thorac Oncol. 2023 Feb;18(2):169-180. doi: 10.1016/j.jtho.2022.10.004. Epub 2022 Oct 25.

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.

Molecules. 2022 Jan 26;27(3):819. doi: 10.3390/molecules27030819.

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.

Cancer Epidemiol. 2022 Feb;76:102080. doi: 10.1016/j.canep.2021.102080. Epub 2021 Dec 15.

Structure-based classification predicts drug response in EGFR-mutant NSCLC.

Nature. 2021 Sep;597(7878):732-737. doi: 10.1038/s41586-021-03898-1. Epub 2021 Sep 15.

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献